Haloperidol
- Generic Name
- Haloperidol
- Brand Names
- Haldol
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23ClFNO2
- CAS Number
- 52-86-8
- Unique Ingredient Identifier
- J6292F8L3D
- Background
Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularl...
- Indication
Haloperidol is indicated for a number of conditions including for the treatment of schizophrenia, for the manifestations of psychotic disorders, for the control of tics and vocal utterances of Tourette’s Disorder in children and adults, for treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted ...
- Associated Conditions
- Aggression, Delirium, Gilles de la Tourette's Syndrome, Huntington's Disease (HD), Nausea and vomiting, Obsessive Compulsive Disorder (OCD), Psychosis, Schizophrenia, Severe Disruptive Behaviour Disorders, Severe Hyperactivity
- Associated Therapies
- -
Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2009-04-01
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 70
- Registration Number
- NCT00838032
- Locations
- 🇨🇳
Mental Health Center of Huaxi Hospital affiliated to Sichuan University, Chengdu, Sichuan, China
Haloperidol vs Olanzapine for the Management of ICU Delirium
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- Richard Hall
- Target Recruit Count
- 200
- Registration Number
- NCT00833300
- Locations
- 🇨🇦
Halifax Infirmary; Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦Victoria General Hospital; Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
A Study in the Treatment of Acute Mania
- Conditions
- Interventions
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2008-10-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 11
- Registration Number
- NCT00767715
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Danderyd, Sweden
Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)
- Conditions
- Interventions
- First Posted Date
- 2008-06-09
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 46
- Registration Number
- NCT00693472
A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Guang Dong Provincial Mental Health Institute
- Target Recruit Count
- 60
- Registration Number
- NCT00642369
- Locations
- 🇨🇳
Guangdong Provincial Mental Health Institute, Guang Zhou, Guangdong, China
Multicenter, Open-Label, Randomised, Haloperidol-controlled Study to Evaluate Seroquel as Mono-Therapy in the Treatment of Agitated Symptoms in the Patients With Acute Episode of Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2012-08-22
- Lead Sponsor
- Peking University
- Target Recruit Count
- 80
- Registration Number
- NCT00631722
Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT00625014
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans
- Conditions
- Interventions
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2008-02-28
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 11
- Registration Number
- NCT00625170
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients
- Conditions
- Interventions
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2018-03-21
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 80
- Registration Number
- NCT00599287
- Locations
- 🇳🇱
University Medical Center, Utrecht, Netherlands
Metabolic Profile and Anthropometric Changes in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2007-09-24
- Lead Sponsor
- Central Institute of Psychiatry, Ranchi, India
- Target Recruit Count
- 2006
- Registration Number
- NCT00534183
- Locations
- 🇮🇳
Central Institute of Psychiatry, Ranchi, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.